scholarly journals Treatment decision making in early-stage papillary thyroid cancer

2017 ◽  
Vol 27 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Thomas A. D'Agostino ◽  
Elyse Shuk ◽  
Erin K. Maloney ◽  
Rebecca Zeuren ◽  
R. Michael Tuttle ◽  
...  
Keyword(s):  
Decision Making ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Early Stage ◽  
Treatment Decision ◽  
Papillary Thyroid ◽  
Treatment Decision Making

scholarly journals Treatment decision making in early-stage papillary thyroid cancer

IBRO Reports ◽  
2019 ◽  
Vol 6 ◽  
pp. S54-S55
Author(s):  
Faezeh Aghayan Kol Kashani ◽  
Amir Hossein Ashna ◽  
Zahra Majdi
Keyword(s):  
Decision Making ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Early Stage ◽  
Treatment Decision ◽  
Papillary Thyroid ◽  
Treatment Decision Making

scholarly journals Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial

Trials ◽  
2010 ◽  
Vol 11 (1) ◽  
Author(s):  
Anna M Sawka ◽  
Sharon Straus ◽  
James D Brierley ◽  
Richard W Tsang ◽  
Lorne Rotstein ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Decision Aid ◽  
Radioactive Iodine ◽  
Early Stage ◽  
Controlled Trial ◽  
Papillary Thyroid ◽  
Randomized Controlled ◽  
Iodine Treatment

Medical Treatment Decision-Making for Advanced, Progressive Medullary Thyroid Cancer

2016 ◽  
pp. 365-374
Author(s):  
Ramona Dadu ◽  
Robert F. Gagel ◽  
Mimi I. Hu
Keyword(s):  
Decision Making ◽  
Thyroid Cancer ◽  
Medical Treatment ◽  
Medullary Thyroid Cancer ◽  
Treatment Decision ◽  
Medullary Thyroid ◽  
Treatment Decision Making

Women's Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk

2007 ◽  
Vol 25 (29) ◽  
pp. 4628-4634 ◽  
Author(s):  
Suzanne C. O'Neill ◽  
Noel T. Brewer ◽  
Sarah E. Lillie ◽  
Edward F. Morrill ◽  
E. Claire Dees ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Early Stage ◽  
Cancer Recurrence ◽  
Treatment Decision ◽  
Recurrence Risk ◽  
Anticipated Regret ◽  
Treatment Decision Making ◽  
Potential Benefits ◽  
Previously Treated

Purpose Genomic and other technologies are improving the accuracy with which clinicians can estimate risk for recurrence (RFR) of breast cancer and make judgments about potential benefits of chemotherapy. Little is known of how patients will respond to genomic RFR testing or interact with their physicians to make informed decisions regarding treatment. We assessed interest in genomic RFR testing and patient preferences for incorporating results into treatment decision making. Patients and Methods One hundred thirty-nine women previously treated for early-stage breast cancer completed surveys that presented hypothetical scenarios reflecting different test outcomes and potential decisions. We assessed women's attitudes toward RFR testing, how results would affect their choices about adjuvant treatment, and potential concerns about and perceived benefits of testing. Results The majority of participants said they would “definitely” want to be tested (76%), receive their results (87%), and discuss these results with their physicians. They were willing to pay, on average, $997 for testing. Those who expressed more concerns about testing were less interested in testing and in incorporating results into treatment decision making. Participants were more likely to want chemotherapy when presented with high-risk results and would worry more about those results. They were least likely to trust and most likely to express potential anticipated regret in response to intermediate RFR results. Conclusion Participants expressed strong interest in testing. Although these decisions were sensitive to RFR, participants’ complex reactions to intermediate RFR suggest care is needed when communicating such results.

“It’s important to me”: A qualitative analysis of shared decision-making and patient preferences in early-stage breast cancer patients.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 227-227
Author(s):  
Valerie Lawhon ◽  
Rebecca England ◽  
Audrey S. Wallace ◽  
Courtney Williams ◽  
Stacey A. Ingram ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Shared Decision Making ◽  
Patient Preferences ◽  
Early Stage ◽  
Treatment Decision ◽  
Treatment Decisions ◽  
Early Stage Breast Cancer ◽  
Shared Decision ◽  
Treatment Decision Making

227 Background: Shared decision-making (SDM) occurs when both patient and provider are involved in the treatment decision-making process. SDM allows patients to understand the pros and cons of different treatments while also helping them select the one that aligns with their care goals when multiple options are available. This qualitative study sought to understand different factors that influence early-stage breast cancer (EBC) patients’ approach in selecting treatment. Methods: This cross-sectional study included women with stage I-III EBC receiving treatment at the University of Alabama at Birmingham from 2017-2018. To understand SDM preferences, patients completed the Control Preferences Scale and a short demographic questionnaire. To understand patient’s values when choosing treatment, semi-structured interviews were conducted to capture patient preferences for making treatment decisions, including surgery, radiation, or systemic treatments. Interviews were audio-recorded, transcribed, and analyzed using NVivo. Two coders analyzed transcripts using a constant comparative method to identify major themes related to decision-making preferences. Results: Amongst the 33 women, the majority of patients (52%) desired shared responsibility in treatment decisions. 52% of patients were age 75+ and 48% of patients were age 65-74, with an average age of 74 (4.2 SD). 21% of patients were African American and 79% were Caucasian. Interviews revealed 19 recurrent treatment decision-making themes, including effectiveness, disease prognosis, physician and others’ opinions, side effects, logistics, personal responsibilites, ability to accomplish daily activities or larger goals, and spirituality. EBC patient preferences varied widely in regards to treatment decision-making. Conclusions: The variety of themes identified in the analysis indicate that there is a large amount of variability to what preferences are most crucial to patients. Providers should consider individual patient needs and desires rather than using a “one size fits all” approach when making treatment decisions. Findings from this study could aid in future SDM implementations.

Sign in / Sign up

Export Citation Format

Share Document